Outcomes of first-line immunotherapy plus chemotherapy or chemotherapy alone based on mismatch repair status: results from a US-based advanced/recurrent endometrial cancer population
IGCS 2026
Adam Pyrzak, Babak Edraki, Helen J. Mackay, Pamela Soliman, Erin Crane, Christopher J. Darus, Melanie Stewart, Shuangxi Ji, Shelley Macneil, Shuyu Li, Rayna Rosati, Alexander Olawaiye
Introduction
Although Phase III trials have shown substantial benefit of first-line (1L) immunotherapy (IO)+chemotherapy (chemo) versus chemo-alone for patients with mismatch repair-deficient (dMMR) advanced/recurrent endometrial cancer (aEC), results have been present (but less pronounced) in those with mismatch repair-proficient (pMMR)-disease. Additionally, acquired resistance to IO may reduce the effectiveness of approved 2L IO-based therapies (eg, IO+tyrosine kinase inhibitor) for pMMR-disease. Our analysis explores real-world clinical effectiveness of 1L IO+chemo versus chemo-alone for aEC.
Methods
Medical data in the Tempus (Chicago, IL, US) database was used to assess progression-free survival (PFS) and overall survival (OS) in patients with aEC who received 1L IO+chemo or chemo, stratified by MMR (immunohistochemistry)/microsatellite-stability (next-generation sequencing) status. Chemo for both cohorts was carboplatin+paclitaxel.
Results
Between 17/9/2019 and 31/8/2024, 290 patients received IO+chemo and 787 received chemo; characteristics were similar between groups (Table-1). Among the IO+chemo group, 76%/23%/1% received pembrolizumab/dostarlimab/durvalumab, respectively. PFS was longer in the IO+chemo group among all-comer patients (HR=0.771;p=0.0256) and the dMMR-cohort (HR=0.405;p=0.0008), but not the pMMR-cohort (HR=0.955;p=0.7227) (Table-2). OS favored IO+chemo among the dMMR-cohort (HR=0.516;p=0.0325) but not among all-comers (HR=0.962; p=0.7428) or the pMMR-cohort (HR=1.114;p=0.3913). PFS/OS trends were similar in the pMMR-cohort, irrespective of TP53-mutation status.
Conclusion/Implications
In this real-world analysis, 1L IO+chemo was not associated with improved PFS/OS among patients with pMMR aEC versus chemo-alone, raising questions about the benefit of adding IO to frontline chemotherapy for pMMR-disease/implications for treatment-sequencing. Given the limitations of retrospective real-world data, our findings should be interpreted with caution and do not support definitive conclusions; additional study is warranted.
Related publications